ABSTRACT Alzheimer's disease (AD) is a risk factor for type 2 diabetes and vice versa, and a growing body of evidence indicates that these diseases are connected both at epidemiological, clinical and molecular levels. Recent studies have begun to reveal common pathogenic mechanisms shared by AD and type 2 diabetes. Impaired neuronal insulin signaling and endoplasmic reticulum (ER) stress are present in animal models of AD, similar to observations in peripheral tissue in T2D. These findings shed light into novel diabetes‐related mechanisms leading to brain dysfunction in AD. Here, we review the literature on selected mechanisms shared between these diseases and discuss how the identification of such mechanisms may lead to novel therapeutic targets in AD. This article is part of the Special Issue entitled ‘Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.’ HighlightsAlzheimer's disease (AD) and type 2 diabetes (T2D) are connected in multiple levels.Molecular mechanisms associated with insulin resistance are shared by AD and T2D.Repurposing antidiabetic drugs for AD has shown promising preclinical results.Novel mechanisms of insulin resistance can be explored in AD drug development.
Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets
M. N. Vieira,R. Lima-Filho,F. D. De Felice
Published 2017 in Neuropharmacology
ABSTRACT
PUBLICATION RECORD
- Publication year
2017
- Venue
Neuropharmacology
- Publication date
2017-11-01
- Fields of study
Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.